Distinguish Parkinson from similar conditions
- Trial ID
- NCT06501469
- Official Title
- Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes
- Goal
- Distinguish Parkinson from similar conditions
- Status
- RECRUITING
- Sponsor
- Non-profit organization for scientific research in Parkinson's disease and related disorders
- Study Type
- OBSERVATIONAL
- Enrollment
- 200 participants
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Atypical Parkinsonism, Parkinsonism
Plain-Language Summary
The goal is to identify biological markers that can tell Parkinson's disease apart from related parkinsonian syndromes and track disease progression, so diagnosis and future treatments can be improved. The team will observe participants over time and collect clinical data, imaging, blood or CSF samples, and digital/monitoring data to find molecules or patterns linked to specific diagnoses and symptoms, no experimental drug is given, and current treatments like levodopa are recorded to see how biomarkers relate to medication response. People who can give written consent are eligible, including those with parkinsonism of any duration and healthy controls; excluded are drug- or metabolic-induced parkinsonism, structural brain lesions that explain symptoms, other serious illnesses with life expectancy under five years, or active participation in other interventional trials.
Locations
- HYGEIA Hospital, Parkinson's disease and Movement Disorders Department, Athens, Greece
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to identify biological markers that can tell Parkinson's disease apart from related parkinsonian syndromes and track disease progression, so diagnosis and future treatments can be improved. The team will observe participants over time and collect clinical data, imaging, blood or CSF samples, and digital/monitoring data to find molecules or patterns linked to specific diagnoses and symptoms, no experimental drug is given, and current treatments like levodopa are recorded to see how biomarkers relate to medication response. People who can give written consent are eligible, including those with parkinsonism of any duration and healthy controls; excluded are drug- or metabolic-induced parkinsonism, structural brain lesions that explain symptoms, other serious illnesses with life expectancy under five years, or active participation in other interventional trials.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 7 years.